Peter Joe Pitts

Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million.

Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC.

Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million.

US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD.

Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million.

Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC.

Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC.

Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC.

Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC.

Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC.

Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC.